# Applying Data Science and AI to Managing Biomedical Portfolios

---

## 🕒 Lesson 18.1: Drug Development Risk & Securitization

### 1. Intuition (ELIF5)
Developing a new medicine is extremely risky and expensive. Imagine going on a quest to find a rare flower in a vast forest where only 1 in 20 paths leads to the flower. If a single researcher takes one path, they will likely fail (95% chance). If we fund 100 researchers to explore 100 different paths at the same time, the chance that at least one of them finds the flower becomes nearly 100%. 
A **Biomedical Megafund** works on this exact principle. By pooling together dozens of independent drug development projects under one giant fund, we lower the overall risk. This allows us to issue bonds (debt) to fund scientific research, attracting large-scale conservative investors (like pension funds) who would never normally invest in early-stage biotechnology.

### 2. Mathematical Formulations
Let $p$ be the independent probability of success for a single clinical drug trial, and let $N$ be the number of independent trials in the portfolio. The probability that at least one drug is successfully approved is given by:
$$P(\text{at least one success}) = 1 - (1 - p)^N$$
To fund the megafund, we apply financial securitization. The cash flows from successful drug approvals are distributed to investors through tranches:
1. **Senior Debt:** Has the first claim on cash flows, offering low yield and very high safety.
2. **Mezzanine Debt:** Has the next claim, offering moderate yield and risk.
3. **Equity:** Receives the remaining cash flows, offering high potential returns but absorbing the first losses.

```text
Algorithm: Megafund Cash Flow Allocation
Input: Drug trial successes K, Drug value V_drug, Senior Debt D_senior, Mezzanine Debt D_mezz
Output: Payout to Senior, Mezzanine, and Equity tranches

Total_Cash = K * V_drug
Payout_Senior = min(Total_Cash, D_senior)
Remaining_Cash = Total_Cash - Payout_Senior
Payout_Mezz = min(Remaining_Cash, D_mezz)
Payout_Equity = Remaining_Cash - Payout_Mezz
return Payout_Senior, Payout_Mezz, Payout_Equity
```

---

## 🕒 Lesson 18.2: AI in Clinical Trial Forecasting

### 1. Intuition (ELIF5)
How do we know which drug projects are worth funding? We can use historical data from thousands of past clinical trials. AI models analyze patient sizes, chemical compound types, and the target diseases to predict whether a new drug will pass its trials, helping us select the best projects for our megafund.

### 2. Mathematical Formulations
We model the probability of trial success $p_k$ for drug $k$ using machine learning classification models (such as random forests or neural networks) trained on trial features $x_k$:
$$p_k = f(x_k; \theta) \in [0, 1]$$
We then optimize the portfolio weights $w_k$ to maximize expected portfolio value subject to value-at-risk limits.
